Skip to main content
. 2016 Nov 8;66(3):613–626. doi: 10.2337/db16-0663

Figure 6.

Figure 6

Administration of ceramide reverses the inhibition of hepatic mitochondrial acetyl-CoA levels and the hepatic PC activities by suppressing intestinal FXR signaling independent of body weight. The Fxrfl/fl and Fxr∆IE mice fed an HFD were injected with or without ceramide for 1 week (n = 7). A: The total and individual ceramide levels in the serum. B: Body weights. C: Fasting plasma glucose levels. D: GTT (left) and area under the curve (AUC) (right). E: PTT (left) and AUC (right). F: Mitochondrial CS activities in the liver. G: Mitochondrial acetyl-CoA concentrations in the liver. H: Mitochondrial PC activities in the liver. Data are presented as the means ± SD. One-way ANOVA with Tukey correction: *P < 0.05 and **P < 0.01 vs. vehicle-treated Fxrfl/fl mice; #P < 0.05 and ##P < 0.01 vs. vehicle-treated Fxr∆IE mice.